Company intelligence / Profile preview

Alpha Cancer Technologies Inc.

Toronto, Ontario, Canadaalpha-cancer.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ACT-101 has been shown to be as safe as placebo in clinical trials in over 300 patients. The company is ready to enter Phase II clinical trials in Myasthenia Gravis and Inflammatory Bowel Disease. Their oncology products have demonstrated excellent safety and significant anti-tumor activity in pre-clinical studies.

Therapeutic areas: GastroenterologyOncologyNeurologyHematology
Modalities: Protein Drug ConjugatesRecombinant human alpha fetoproteinAntibody-drug conjugatesRadiopharmaceuticals
Industry: Biotech

Drug pipeline

6 assets

ACT-901

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

Bristol-Myers Squibb (14% equity shareholder with no other commercial rights)

Beyond the preview

Go deeper on Alpha Cancer Technologies Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha Cancer Technologies Inc..

Explore the full profile